Company at a Glance
Lumenis is the world’s largest energy-based medical device company for surgical, ophthalmology and aesthetic solutions. As an international leader in the development and commercialization of innovative energy-based technologies, including laser, Intense Pulsed Light (IPL), Radio-Frequency (RF) and Ultrasound, Lumenis has redefined medical treatments and set numerous technological and clinical gold standards.
Lumenis’ vision is to provide better technology for better patient care through innovative energy-based solutions. With a ground-breaking technological legacy of more than 50 years, we are committed to enhancing patient health and quality of life; addressing new and growing needs of aging populations; and offering medical professionals innovative solutions to meet the developing and dynamic healthcare environment of the 21st century.
Lumenis operates in three core markets: Surgical, Ophthalmology and Aesthetics. Throughout our history, Lumenis has created innovative solutions for previously untreatable conditions and designed advanced technologies that have revolutionized existing treatment methods in each and every one of the sectors we operate in.
With more than 20 new products launched since 2010 and multiple new applications in the pipeline, Lumenis is poised to maintain and grow our leadership position, bringing our advanced technological innovations to patients all over the globe.
Technology & Product(s)
We pioneered the development of high-powered holmium lasers for the urology application, including the HoLEP procedure for the minimally invasive treatment of benign prostatic hyperplasia (BPH), and urinary lithotripsy. HoLEP, the use of our high-powered holmium laser (the Lumenis Pulse™ 120H) to perform enucleation of the prostate, has proven to be more effective than alternatives while minimizing collateral tissue damage and demonstrating the lowest recurrence rates. In addition, the high-power, high-repetition holmium laser is an effective form of treatment for a broad range of urinary and kidney stones, enabling stone dusting, which reduces the stones to minimally sized particles and allows them to be self-cleared.
Our CO2 laser-based product line (The UltraPulse® DUO and AcuPulse™ DUO) is a leader in the treatment of benign and malignant lesions and inflammations in the ear, nose and throat (ENT) laser market, using innovative technology, including guidance technology, which provides advanced precision with minimal collateral tissue damage compared to other alternatives. Our CO2 laser application for vocal chords rescission provides better patient outcomes and lower overall costs to the healthcare system.
In Gynecology, Lumenis leads the way, offering smart CO2 laser solutions providing gynecologists and fertility experts with an ultra-precise and flexible CO2 laser solution for treatments of endometriosis, uterine fibroids, adhesions and vaginal health-related conditions.
Objectives: We would like significantly enhance our presence in the Urology, ENT and GYN. clinical areas in any given country in general and in EMEA region in particular
Target businesses: Distributers, located in EMEA, who are specialized in selling capital systems and disposables products in Urology, ENT and GYN.
Target Countries: Any country located within EMEA